Moreover, exosomal GPC1 derived from all PDAC patients (100%) was significantly higher than that derived from healthy controls.[140] This is a proof of concept that exosomal GPC1 has the potential to provide a promising biomarker specifically for pancreatic cancers. Here, GPC1 is linked to pancreatic neoplasm.